AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10165968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 2213773 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole (20 mg/kg/day) 2 days a week for 12 weeks
Number of subjects: 73
Study 2213773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 666929 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia
Number of subjects: 21
Study 666929 — intervention group
Group type: COMPARATOR
Intervention: Narcotic analgesia
Number of subjects: 21
Study 31347385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib alongside chemotherapy followed by placebo maintenance (arm B)
Number of subjects: 0
Study 31347385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib throughout both periods (arm C)
Number of subjects: 0
Study 31347385 — intervention group
Group type: COMPARATOR
Intervention: Placebo during chemotherapy and maintenance (arm A)
Number of subjects: 0
Study 29273007 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
Number of subjects: 83
Study 29273007 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2
Number of subjects: 83
Study 26012890 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CBT for insomnia
Number of subjects: 63
Study 26012890 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 63
Study 23725564 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-choice condition (able to choose story components)
Number of subjects: 26
Study 23725564 — intervention group
Group type: COMPARATOR
Intervention: No-choice condition (story components were preselected)
Number of subjects: 26
Study 21964428 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 ingestion at 60 minutes before exercise (H1)
Number of subjects: 8
Study 21964428 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 ingestion at 120 minutes before exercise (H2)
Number of subjects: 8
Study 21964428 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 ingestion at 180 minutes before exercise (H3)
Number of subjects: 8
Study 19445661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cholecystectomy during standard surgery for curable gastric cancer (subtotal or total gastrectomy)
Number of subjects: 0
Study 19445661 — intervention group
Group type: COMPARATOR
Intervention: Standard gastric surgery only
Number of subjects: 0
Study 17868430 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg q.d.
Number of subjects: 1238
Study 17868430 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg b.i.d.
Number of subjects: 1238
Study 17868430 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 20 mg b.i.d.
Number of subjects: 1238
Study 17868430 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 30 mg b.i.d.
Number of subjects: 1238
Study 17868430 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (titrated to INR 1.8-3.0)
Number of subjects: 1238
Study 17868430 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (all doses)
Number of subjects: 1238
Study 15135472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB) using a peritumoural injection technique with blue dye and radiolabelled colloid mapping
Number of subjects: 75
Study 15135472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 75
Study 15135472 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard axillary treatment after SNB
Number of subjects: 75
Study 12503706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 microg, twice daily for 12 weeks
Number of subjects: 68
Study 12503706 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 12 weeks
Number of subjects: 68
Study 10187069 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement strategies including development of leadership skills, focus on internal quality, ongoing training and staff development, and efficient use of resources.
Number of subjects: 0
Study 8715262 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of training by microcomputers
Number of subjects: 16
Study 8715262 — intervention group
Group type: COMPARATOR
Intervention: Noncomputer assisted evaluation
Number of subjects: 16
Study 31899848 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. nadroparin (171 IU/kg/d)
Number of subjects: 178
Study 29386889 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 μg
Number of subjects: 0
Study 29386889 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 62.5 μg
Number of subjects: 0
Study 29386889 — intervention group
Group type: EXPERIMENTAL
Intervention: VI 25 μg
Number of subjects: 0
Study 29386889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27067889 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive programme (Nourishing Start for Health - NOSH) for up to 6 months duration, delivered by healthcare professionals
Number of subjects: 10833
Study 27067889 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no offer of NOSH intervention)
Number of subjects: 10833
Study 26333499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 g/(kg.h) for 10 min, then 0.3 g/(kg.h) for 20 min)
Number of subjects: 90
Study 26333499 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg for 60 s, then 0.04 mg/(kg.h) for 20 min)
Number of subjects: 90
Study 26333499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 90
Study 22940561 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids alone
Number of subjects: 115
Study 22940561 — intervention group
Group type: EXPERIMENTAL
Intervention: BZDs concurrent with opioids
Number of subjects: 115
Study 22940561 — intervention group
Group type: EXPERIMENTAL
Intervention: BZDs alone
Number of subjects: 115
Study 22940561 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither opioids nor BZDs
Number of subjects: 115
Study 22940561 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BZDs and opioids
Number of subjects: 115
Study 20626357 — intervention group
Group type: EXPERIMENTAL
Intervention: Red LED-powered transillumination (TM group, n=67)
Number of subjects: 136
Study 20626357 — intervention group
Group type: COMPARATOR
Intervention: Usual method (UM group, n=69)
Number of subjects: 136
Study 20626357 — intervention group
Group type: EXPERIMENTAL
Intervention: Red LED-powered transillumination (TM group, n=44)
Number of subjects: 136
Study 19571699 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-hour-stay laparoscopic colectomy
Number of subjects: 10
Study 16458681 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% eyedrops (GAT group)
Number of subjects: 104
Study 16458681 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 0.3% eyedrops (CIP group)
Number of subjects: 104
Study 15239087 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal banding ligation (VBL)
Number of subjects: 152
Study 15239087 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (PPL)
Number of subjects: 152
Study 11297596 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg) plus Vitamin D(3) (800 IU)
Number of subjects: 148
Study 11297596 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1200 mg/day)
Number of subjects: 148
Study 9279723 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (ProCT) measurement
Number of subjects: 155
Study 8282390 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 90
Study 8282390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 3730140 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic instruction
Number of subjects: 26
Study 3730140 — intervention group
Group type: COMPARATOR
Intervention: Holistic instruction
Number of subjects: 26
Study 31606265 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-17A treatment
Number of subjects: 150
Study 31606265 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine treatment
Number of subjects: 150
Study 28316267 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Psychostimulation Program (IPP), 90 min/d, 4 d/week for 8 weeks
Number of subjects: 40
Study 28316267 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT), 60 min/d, 4 d/week for 8 weeks
Number of subjects: 40
Study 28316267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 26841367 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual participant data NMA
Number of subjects: 0
Study 26841367 — intervention group
Group type: COMPARATOR
Intervention: Aggregate data NMA
Number of subjects: 0
Study 24907778 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving multiple HIV prevention messages (about PrEP, nPEP, rectal microbicides, and condoms)
Number of subjects: 803
Study 24907778 — intervention group
Group type: COMPARATOR
Intervention: Receiving one, two, or four HIV prevention messages
Number of subjects: 803
Study 22705148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild to moderate cognitive impairment
Number of subjects: 173
Study 22705148 — intervention group
Group type: COMPARATOR
Intervention: Male gender
Number of subjects: 173
Study 22705148 — intervention group
Group type: COMPARATOR
Intervention: Low BMI
Number of subjects: 173
Study 22705148 — intervention group
Group type: COMPARATOR
Intervention: Baseline 25‐hydroxyvitamin D level
Number of subjects: 173
Study 20502997 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 249
Study 20502997 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 249
Study 18720689 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg daily plus oral levamisole 2.5 mg/kg/wk (up to 150 mg/wk)
Number of subjects: 60
Study 18720689 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg daily
Number of subjects: 60
Study 16003426 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised matching method using digital images
Number of subjects: 10
Study 16003426 — intervention group
Group type: COMPARATOR
Intervention: Conventional matching method simulated in a phantom head
Number of subjects: 10
Study 16003426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (computer and conventional)
Number of subjects: 10
Study 12462431 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid (AMX/CA) 875/125 mg b.i.d. for 14 days
Number of subjects: 206
Study 12462431 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil 500 mg b.i.d. for 14 days
Number of subjects: 206
Study 10526726 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU/day)
Number of subjects: 42
Study 10526726 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 42
Study 7729023 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators
Number of subjects: 31
Study 7729023 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock or antitachycardia pacing therapy
Number of subjects: 31
Study 7729023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachycardia rates > 240 beats per minute
Number of subjects: 31
Study 1781288 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine A (0.05 mg bid for 4 weeks for multi-infarct dementia; 0.03 mg bid for 2 weeks for senile and presenile simple memory disorders)
Number of subjects: 160
Study 1781288 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 160
Study 6452948 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan
Number of subjects: 127
Study 6452948 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU and methyl‐CCNU
Number of subjects: 127
Study 6452948 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU, methyl‐CCNU, and streptozocin
Number of subjects: 127
Study 6452948 — intervention group
Group type: COMPARATOR
Intervention: VP‐16‐213
Number of subjects: 127
Study 6452948 — intervention group
Group type: EXPERIMENTAL
Intervention: two‐ and three‐drug combinations
Number of subjects: 127
Study 6452948 — intervention group
Group type: EXPERIMENTAL
Intervention: three treatment regimens
Number of subjects: 127
Study 31651370 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide (ETL) administered intravenously after every hemodialysis session for 12 months
Number of subjects: 62
Study 31651370 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol administered intravenously after every hemodialysis session for 12 months
Number of subjects: 62
Study 31651370 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide (ETL)
Number of subjects: 62
Study 31651370 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 62
Study 27678271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (20 mL of 0.5% bupivacaine)
Number of subjects: 100
Study 27678271 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (20 mL of 0.9% normal saline)
Number of subjects: 100
Study 25251885 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Injectable Heroin (SIH)
Number of subjects: 127
Study 25251885 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Injectable Methadone (SIM)
Number of subjects: 127
Study 25251885 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized Oral Methadone (OOM)
Number of subjects: 127
Study 24052362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (15 mg)
Number of subjects: 120
Study 24052362 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (5-10 mg)
Number of subjects: 120
Study 23044558 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mometasone ointment used twice a day for the first month and then once a day for 6 months on a few grafted lesions
Number of subjects: 11
Study 19571545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 96
Study 19571545 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 96
Study 17420168 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GDP PD solution
Number of subjects: 21
Study 17420168 — intervention group
Group type: COMPARATOR
Intervention: Low-GDP PD solution
Number of subjects: 21
Study 15689069 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg body weight dihydroartemisinin (DHA)
Number of subjects: 20
Study 15689069 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg body weight dihydroartemisinin (DHA)
Number of subjects: 20
Study 15689069 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg body weight oral artesunate (AS)
Number of subjects: 20
Study 15689069 — intervention group
Group type: COMPARATOR
Intervention: oral artesunate (AS)
Number of subjects: 20
Study 11176547 — intervention group
Group type: EXPERIMENTAL
Intervention: Long instrument
Number of subjects: 290
Study 11176547 — intervention group
Group type: EXPERIMENTAL
Intervention: Short instrument
Number of subjects: 290
Study 11176547 — intervention group
Group type: COMPARATOR
Intervention: Control group (not asked about expectations)
Number of subjects: 290
Study 9395031 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 3
Study 9395031 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin
Number of subjects: 3
Study 7535990 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (400 ml per day, 11% alcohol)
Number of subjects: 20
Study 7535990 — intervention group
Group type: COMPARATOR
Intervention: White wine (400 ml per day, 11% alcohol)
Number of subjects: 20
Study 7535990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both red and white wine
Number of subjects: 20
Study 7535990 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 20
Study 7535990 — intervention group
Group type: COMPARATOR
Intervention: White wine
Number of subjects: 20
Study 3239522 — intervention group
Group type: EXPERIMENTAL
Intervention: OK432 intradermal administration
Number of subjects: 29
Study 3239522 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy (Control)
Number of subjects: 29
Study 31565758 — intervention group
Group type: EXPERIMENTAL
Intervention: UV photo intervention
Number of subjects: 167
Study 31565758 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion exercise with UV photo
Number of subjects: 167
Study 31565758 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation exercise with UV photo
Number of subjects: 167
Study 31565758 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion and self-affirmation with UV photo
Number of subjects: 167
Study 31565758 — intervention group
Group type: COMPARATOR
Intervention: Neutral essay
Number of subjects: 167
Study 30662331 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 127
Study 30662331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination panel of ALT, HOMA-IR, and RBP4
Number of subjects: 127
Study 30662331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 127
Study 30662331 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic test
Number of subjects: 127
Study 30662331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty Liver Index (FLI)
Number of subjects: 127
Study 28612975 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch injury (ESI) performed at day 8 or 9 of stimulation phase in the IUI cycle
Number of subjects: 150
Study 28612975 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 150
Study 28612975 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch injury (ESI)
Number of subjects: 150
Study 25801553 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.0 mg of sublingual artemether (5 × 3.0 actuations)
Number of subjects: 16
Study 25801553 — intervention group
Group type: EXPERIMENTAL
Intervention: 30.0 mg of sublingual artemether (10 × 3.0 mg)
Number of subjects: 16
Study 25801553 — intervention group
Group type: EXPERIMENTAL
Intervention: 30.0 mg of sublingual artemether (5 × 6.0 mg)
Number of subjects: 16
Study 25801553 — intervention group
Group type: COMPARATOR
Intervention: 30.0 mg of artemether in tablet form
Number of subjects: 16
Study 25801553 — intervention group
Group type: EXPERIMENTAL
Intervention: 30.0 mg of sublingual artemether given over 5 days as either 10 3.0‐mg or 5 6.0‐mg actuations
Number of subjects: 16
Study 23711188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin daily for 28 days
Number of subjects: 0
Study 23711188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 23711188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21850387 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg, range 10-40 mg)
Number of subjects: 48
Study 21850387 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 48
Study 21850387 — intervention group
Group type: COMPARATOR
Intervention: Control (no olmesartan)
Number of subjects: 48
Study 21850387 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan and Control
Number of subjects: 48
Study 19272375 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 250 mg naproxen
Number of subjects: 11
Study 19272375 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 50 mg diclofenac
Number of subjects: 11
Study 19272375 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 1 g acetaminophen
Number of subjects: 11
Study 19272375 — intervention group
Group type: COMPARATOR
Intervention: 3 x 1 placebo
Number of subjects: 11
Study 17236771 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT)
Number of subjects: 2208
Study 17236771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy (Mx)
Number of subjects: 2208
Study 17236771 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide local excision (WLE)
Number of subjects: 2208
Study 17236771 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET)
Number of subjects: 2208
Study 17236771 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <50 years (proxy pre-menopausal)
Number of subjects: 2208
Study 17236771 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall QOL and mental health
Number of subjects: 2208
Study 15709456 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (MON; 10 mg daily)
Number of subjects: 40
Study 15709456 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (ZAF; 40 mg daily)
Number of subjects: 40
Study 12191965 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine levels
Number of subjects: 0
Study 12191965 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria (none, trace, overt)
Number of subjects: 0
Study 12191965 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid levels
Number of subjects: 0
Study 9737821 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral controlled release tablet (A)
Number of subjects: 12
Study 9737821 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg aqueous solution retained in the mouth for 10 min (B)
Number of subjects: 12
Study 9737821 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg bioadhesive buccal tablet placed between the lower gum and lip for 6 h (C)
Number of subjects: 12
Study 7856622 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-375 mg/day in two or three divided doses)
Number of subjects: 0
Study 7856622 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 2563045 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (30 cm2 for heavy smokers, 20 cm2 for others)
Number of subjects: 199
Study 2563045 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 199
Study 2563045 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 199
Study 808082 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium cromoglycate
Number of subjects: 23
Study 808082 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study 30817455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 1347